or, Crestor's "Jupiter" Study is a three bagger!
It's very hard to imagine why anyone would, after today, pay for a three- to ten-times more expensive placebo, when 48 percent reductions in CV event risks are being achieved on statins (albeit a rather pricey, branded statin). In my estimation, plain old generic statins are sure to benefit from this data, as well. So, stick a fork in Vytorin/Zetia -- that barbeque is over:
. . . .“Compared to those who received placebo, patients receiving the drug rosuvastatin also had a 48 percent reduction in stroke, a 46 percent reduction in the need for interventions to reopen blocked blood vessels and a 20 percent drop in all-cause mortality,” said Paul M. Ridker, M.D., lead author of the study and director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, Mass. . . .
No comments:
Post a Comment